Stockreport

ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update    

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market $100 billion.Inflammasome ASC Inhibitor [Read more]